Detalhe da pesquisa
1.
Amoxicillin-clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626241
2.
7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
J Antimicrob Chemother
; 79(2): 360-369, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113528
3.
Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex.
Clin Infect Dis
; 76(Suppl 2): S166-S178, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125466
4.
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020).
Antimicrob Agents Chemother
; 67(4): e0152522, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877017
5.
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Eur J Clin Microbiol Infect Dis
; 42(4): 453-459, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810724
6.
In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020).
Antimicrob Agents Chemother
; 66(10): e0121422, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169327
7.
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Antimicrob Agents Chemother
; 66(2): e0166721, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807761
8.
In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized ß-lactamase genes.
J Antimicrob Chemother
; 77(3): 689-694, 2022 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34849977
9.
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a ß-lactam/ß-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
J Antimicrob Chemother
; 77(10): 2642-2649, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35897129
10.
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020).
Eur J Clin Microbiol Infect Dis
; 41(3): 477-487, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041100
11.
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.
J Antimicrob Chemother
; 76(12): 3125-3134, 2021 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34459890
12.
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
J Antimicrob Chemother
; 76(3): 659-666, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33276387
13.
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
J Antimicrob Chemother
; 76(11): 2833-2838, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436603
14.
Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094137
15.
Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018.
Antimicrob Agents Chemother
; 64(2)2020 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31712207
16.
In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae, Including Molecularly Characterized Strains.
Antimicrob Agents Chemother
; 65(1)2020 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077651
17.
Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015026
18.
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
Antimicrob Agents Chemother
; 64(6)2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179519
19.
In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32071042
20.
Amoxicillin/clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709848